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The statin drug lovastatin normalizes excessive protein synthesis and thereby ameliorates 
pathological changes in animal models of Fragile X Syndrome (FX), the most commonly identified 
genetic cause of autism. Recently, we compared the efficacy of lovastatin to the more potent and 
brain-penetrant drug simvastatin for correcting phenotypes in the Fmr1-/y mouse (Muscas et al., 
2019). Surprisingly, we find simvastatin worsens excessive protein synthesis and has no impact on 
audiogenic seizures (AGS) in Fmr1-/y mice, suggesting it does not work in a similar fashion to 
lovastatin. A recent commentary by Ottenhoff et al. suggests that differences in dose and/or study 
design might account for our results. Here we discuss the points raised by Ottenhoff et al., as well 
as the evidence supporting a therapeutic role for lovastatin versus simvastatin. We conclude that 
differences between lovastatin and simvastatin warrant careful consideration with respect to the 
treatment of neurodevelopmental disorders. 
 
Main text: 
Therapeutic strategies that reduce protein synthesis have shown efficacy in reducing pathological 
brain phenotypes in FX (Stoppel et al., 2017; Protic et al., 2019). In the FX (Fmr1-/y) mouse model, 
lovastatin reduces the activation of Ras and downstream extracellular regulated-kinase (ERK) 
signalling, thereby normalizing protein synthesis and correcting changes in synaptic plasticity, 
neuronal hyperexcitability, epileptogenesis and learning (Osterweil et al., 2013; Sidorov et al., 
2014) (Table 1). In the Fmr1-/y rat model, early administration of lovastatin prevents emergence of 
plasticity deficits and learning deficiencies later in development (Asiminas et al., 2019). In recent 
work we tested whether the structurally similar drug simvastatin could correct core phenotypes of 
excessive hippocampal protein synthesis and audiogenic seizures (AGS) in the Fmr1-/y mouse 
(Muscas et al., 2019). The motivation for testing simvastatin versus lovastatin is a two- to four-fold 
increase in potency, increased brain penetrance, and wider availability in Europe (Schachter, 2005). 
However, simvastatin has not been tested in any model of FX, and preclinical evidence of efficacy 
was required before incurring the significant cost of a clinical trial. This is particularly relevant for 
simvastatin, which has been tested for the treatment of Neurofibromatosis Type 1 (NF1), a 
neurodevelopmental disorder characterized by excessive Ras-ERK signalling. Early studies in the 
Nf1+/- mouse showed a significant correction of several brain phenotypes with lovastatin (Li et al., 
2005). Assuming the mechanisms for reversing pathological changes were identical for lovastatin 
and simvastatin, clinical trials were initiated for simvastatin in NF1 despite the absence of animal 
model studies. To date, three randomized placebo-controlled clinical trials for simvastatin in NF1 
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have failed to show a significant improvement in primary outcome measures (Krab et al., 2008; van 
der Vaart et al., 2013; Stivaros et al., 2018) (Table 2).  
To our surprise, the comparison of lovastatin and simvastatin in the FX mouse model 
revealed significant differences. While lovastatin reduces protein synthesis in Fmr1-/y hippocampus 
to WT levels, simvastatin resulted in a significant increase in protein synthesis in both genotypes 
(Fig. 1A). In contrast to lovastatin, simvastatin does not reduce ERK activation in Fmr1-/y 
hippocampus, which is a key driver of the excess protein synthesis phenotype (Osterweil et al., 
2010; Muscas et al., 2019). Moreover, simvastatin does not reduce the incidence of AGS in Fmr1-/y 
mice, even when administered at a limiting high dose (Fig. 1B). In contrast, lovastatin treated 
cohorts show a significant reduction in seizure incidence, consistent with previous work (Fig. 1C) 
(Osterweil et al., 2013). From these results we conclude that lovastatin and simvastatin do not work 
in a similar fashion with respect to FX models, and suggest caution should be used when assuming 
these compounds are interchangeable. Our results have been discussed in a recent commentary by 
Ottenhoff et al., who have been involved in clinical trials with simvastatin for the treatment of NF1 
(Krab et al., 2008; van der Vaart et al., 2013; Stivaros et al., 2018; Ottenhoff et al., 2020). The 
authors raise points regarding our study design, suggesting differences in dose and/or study design 
might account for the failure of simvastatin to correct Fmr1-/y phenotypes. Here we discuss these 
points and examine the evidence supporting lovastatin versus simvastatin for the treatment of 
neurodevelopmental disorders. 
 
Different actions on protein synthesis 
Multiple treatments that normalize excess protein synthesis also ameliorate epileptogenic and 
behavioural phenotypes in FX models (Dolen et al., 2007; Liu et al., 2011; Gkogkas et al., 2014; 
Gantois et al., 2017; Stoppel et al., 2017).  To investigate whether simvastatin corrects the excessive 
protein synthesis phenotype in the Fmr1-/y mouse we utilized a metabolic labelling assay in 
hippocampal slices that has been employed in previous studies (Osterweil et al., 2010). As the 
potency of simvastatin is 2- to 4-fold that of lovastatin (Schaefer et al., 2004), we chose a starting 
dose of 5 µM, which is half the 10 µM starting dose of lovastatin used in previous work (Osterweil 
et al., 2013). Remarkably, this relatively modest dose of simvastatin caused a 50-60% increase in 
protein synthesis in both WT and Fmr1-/y slices, dramatically worsening the protein synthesis 
phenotype (Fig. 1A) (Muscas et al., 2019). Given these results, we reasoned that increasing 
concentration would not only be ineffective, it would have deleterious consequences for both WT 
and Fmr1-/y hippocampus. Instead, we tested whether a lower dose range of 0.1-0.5 µM simvastatin 
might mitigate potential off-target effects and reduce the protein synthesis phenotype. 
Unfortunately, increased protein synthesis continued to be seen in slices treated at these lower doses 
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(Fig. 1A). In contrast, WT/Fmr1-/y littermates treated with 50 µM lovastatin resulted in the expected 
decrease in protein synthesis in Fmr1-/y slices.  
Looking at these results it is clear that under conditions where lovastatin normalizes protein 
synthesis in the Fmr1-/y hippocampus, simvastatin causes a dramatic worsening of this core 
phenotype. Regarding these results, Ottenhoff et al. state: 
“the most surprising finding of the study by Muscas and colleagues is the finding that 
simvastatin treatment at low dose actually worsened the Fmr1 phenotype by further increasing 
protein synthesis rates. (…) For the follow-up of these trials it would be of great importance to 
know if a comparable (low) dose of lovastatin (below the doses needed to inhibit ERK) would 
have a similar negative effect on this phenotype, especially since the dose that can be safely used 
in clinical trials is much lower than the in vivo dose used in this study”.  
We note that dose-response studies have in fact shown that lovastatin decreases protein synthesis at 
1, 10 and 20 µM in cultured neuroblasts (Santa-Catalina et al., 2008). In hippocampal slices we 
have established that a lower dose of 10 µM lovastatin does not cause a significant reduction in 
protein synthesis, however it certainly does not cause the dramatic increase seen with simvastatin 
(Fig. 1A) (Osterweil et al., 2013). In contrast, the impact of simvastatin on protein synthesis in 
neuronal cells has not been determined. The study cited by Ottenhoff et al. describes experiments 
performed in a muscle-derived C2C12 cell line, and it is not unreasonable to expect that the 
response in the nervous system will differ (Tuckow et al., 2011). Indeed, simvastatin has been 
shown to have a number of brain-specific effects that could contribute to the rise in protein 
synthesis, including a stimulation of neurotrophin release and augmentation of the expression and 
activation of NMDA-type glutamate receptors (NMDARs) (Parent et al., 2014; Roy et al., 2015; 
Chen et al., 2016). With respect to the latter, acute application of simvastatin has been shown to 
enhance surface expression and current flow through NMDARs in hippocampal slices, increasing 
the magnitude of long-term potentiation (LTP) (Parent et al., 2014; Chen et al., 2016). The changes 
in calcium influx and downstream signaling that are associated with NMDAR activation could 
contribute to the rise of protein synthesis we observe. In contrast, lovastatin has been shown to 
downregulate the GluN2B subunit of the NMDAR and thereby reduce associated signaling (Huo et 
al., 2014). This opposing action on NMDARs may contribute to the differential action on protein 
synthesis in hippocampal slices.  
However, it should be noted that longer treatments with simvastatin, lovastatin and other 
statins reduce the production of cholesterol needed to stabilize NMDARs at the cell surface, 
ultimately causing a mild reduction in activity (Zacco et al., 2003; Ponce et al., 2008; Huo et al., 
2014; McFarland et al., 2014). Therefore, longer-term experiments testing protein synthesis at 
multiple timepoints post simvastatin treatment are needed to determine whether changes in 
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NMDAR activity are involved. What we can conclude for now is that the differential impact of 
lovastatin and simvastatin on basal protein synthesis is striking, and should be investigated in 
follow up studies.  
 
Different actions on ERK 
Statins inhibit the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase pathway 
that produces both cholesterol and isoprenoid intermediates, which are important substrates for the 
posttranslational modification and activation of many proteins (Liao & Laufs 2005; Ling & Tejada-
Simon 2016; Nürenberg & Volmer 2012). Lovastatin has been shown to inhibit the Ras 
farnesylation required for membrane association and subsequent activation of the ERK pathway 
(Schafer et al., 1989; Mendola and Backer, 1990; Li et al., 2005). In our comparison study we find 
that the low doses of simvastatin that raise protein synthesis have no significant impact on ERK 
activation in the Fmr1-/y hippocampus (Muscas et al., 2019). Ottenhoff et al. argue that this result 
conflicts with previous work that shows “like lovastatin, simvastatin has been shown to decrease 
ERK signalling “. We note that the simvastatin dose used in our study is low due to the impact of 
higher doses on protein synthesis, and it may be that higher doses of simvastatin ultimately show an 
inhibitory effect on ERK. However, it is important to consider that the cited studies either do not 
measure ERK (Guillen et al., 2004; Ghittoni et al., 2006; Ghosh et al., 2009) , or show that 
simvastatin reduces ERK signalling in non-neuronal cells only when Ras-ERK is hyper-stimulated, 
but not under basal conditions (Furst et al., 2002; Miura et al., 2004; Ghittoni et al., 2005; Khanzada 
et al., 2006; Ogunwobi and Beales, 2008; Sundararaj et al., 2008; Kang et al., 2009; Chen et al., 
2010; Lee et al., 2011; Takayama et al., 2011).  
Unlike simvastatin, lovastatin has been shown to reduce basal Ras-ERK signalling in the 
absence of activation (Santa-Catalina et al., 2008; Osterweil et al., 2013). This point is particularly 
relevant to the protein synthesis phenotype in FX, which is not due to a hyperactivation of the ERK 
pathway but rather a hypersensitive response to normal levels of ERK signalling (Osterweil et al., 
2010). It is also important to point out that clinical studies of platelets isolated from simvastatin-
treated NF1 patients show no significant reduction in basal ERK activation (Stivaros et al., 2018), 
whereas those isolated from lovastatin-treated FX patients exhibit a robust reduction in ERK 
signalling that is correlated with treatment efficacy (Pellerin et al., 2016). Future studies examining 
the mechanistic differences between these statins could be particularly valuable for understanding 
the impact on neurological phenotypes.  
 
Different actions on audiogenic seizures 
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The AGS phenotype has been used to test multiple potential pharmacological strategies that have 
moved on to clinical investigation in FX, including lovastatin (Yan et al., 2005; Liu et al., 2012; 
Busquets-Garcia et al., 2013; Osterweil et al., 2013; Gkogkas et al., 2014; Gantois et al., 2017; 
Stoppel et al., 2017). In Muscas et al. we compared acute injection of 100 mg/kg lovastatin to an 
equipotent dose of 50 mg/kg simvastatin. The results show a clear reduction in seizure incidence 
and severity with lovastatin, and no effect of simvastatin (Fig. 1B). Although Ottenhoff et al. argue 
“there is no experiment in which lovastatin and simvastatin are compared at the same dose (and 
with the same vehicle)”, the differential potency of these drugs has been well established 
(Schachter, 2005). If the question is whether there is an equivalent impact of these drugs, we would 
argue equivalent potency is a key point. Moreover, our attempts to increase simvastatin to 100 
mg/kg revealed deleterious side effects that would have made it impossible to make a meaningful 
comparison.  
Ottenhoff et al. bring up the important point that “the dose in which a particular drug 
rescues a phenotype in animal model does not always translate into a clinically applicable and safe 
dose in humans.” In our study we compared acute injections of relatively high doses of lovastatin 
and simvastatin due to the rapid action of these higher doses on the AGS phenotype (Osterweil et 
al., 2013). However, we also tested a lower dose of 3 mg/kg that is consistent with the dose given to 
humans according to standard calculations (Nair and Jacob, 2016)(Fig. 1B). Similar to the higher 
dose of simvastatin, the 3 mg/kg dose also failed to reduce seizures in the Fmr1-/y mouse. In 
contrast, a range of lovastatin doses correct the AGS phenotype in Fmr1-/y mice including a 2-day 
10 mg/kg oral administration that is consistent with a human dose (Fig. 1C). This correction of 
AGS with lovastatin is seen whether Fmr1-/y mice are bred on the FVB or C57BL6 background 
strains  (Osterweil et al., 2013). Ottenhoff et al. argue “if a behavioral rescue is observed in young 
mice (e.g. the rescue of seizures in Fmr1 mice was performed on P18-P29 mice, Osterweil et al., 
2013; Muscas et al., 2019), it is important to investigate if such a rescue is still observed when the 
brain has fully matured.” We note that multiple studies in mouse and rat models of FX and other 
neurodevelopmental disorders have shown that lovastatin corrects pathological phenotypes over a 
range of animal ages, including adults (Table 1).  In contrast, beyond our study, there is no previous 
work examining simvastatin in any animal model of neurodevelopmental disorders including the 
Nf1+/- mouse.  
 
Study design 
From the side-by-side experiments comparing lovastatin versus simvastatin we conclude there are 
differences in mechanism and efficacy that should be considered and further investigated in 
additional animal model studies. Ottenhoff et al. question whether the differences we report are in 
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fact significant, stating “the drugs should not only be tested side-by-side as interleaved experiments, 
they should also directly be compared with each other using a statistical analysis that tests for a 
main effect of treatment, and if significant, followed by a post-hoc analysis to compare the drugs”. 
Our experimental design compares lovastatin and simvastatin to matched vehicle groups, rather 
than directly to one another, because different concentrations of DMSO were needed for each drug. 
The blinded comparison of drug groups to counter-balanced vehicle controls is considered good 
practice by multiple authorities on experimental design for laboratory animals (Festing and Altman, 
2002).  
In order to evaluate the effects of lovastatin and simvastatin on seizure incidence we used a 
Fisher’s Exact test that allows for comparisons between small (< 50) nominal (yes/no) datasets, 
consistent with previous AGS studies (Pacey et al., 2009; Osterweil et al., 2010; Henderson et al., 
2012; Michalon et al., 2012; Ronesi et al., 2012; Osterweil et al., 2013; Gross et al., 2015; Thomson 
et al., 2017). We find a significant difference in seizure incidence between vehicle and lovastatin-
treated Fmr1-/y mice (48%, p = 0.0136), but not vehicle vs low-dose simvastatin (0%, p >0.999) or 
vehicle vs high-dose simvastatin (9%, p = 0.6968) (Fig. 1C). However, Ottenhoff et al. suggest that 
fitting our data to a logistical regression model is a better approach for determining global effects of 
treatment and genotype in all groups. They go on to fit our data to a model and state that it  
“shows a trend for a main effect of treatment (2(6)=12; p=0.07), but not for the interaction 
between genotype and treatment (2(4)=4; p=0.3). When performing a post-hoc Tukey’s test, 
neither the Fmr1-lovastatin versus Fmr1 ‘low dose’ of simvastatin (p= 0.96) nor the Fmr1-
lovastatin versus Fmr1-‘high dose’ of simvastatin treatment (p>0.99) are significantly different 
from each other. Hence, despite the fact that the lovastatin dose was 2-30 fold higher than 
simvastatin dose, it does not seem to perform significantly better than simvastatin in this seizure 
assay.”  
To investigate this issue, we examined the R script used to run the logistical regression model 
(shared by Ottenhoff et al.). Our analysis revealed a script error that led to the wrong reporting of p-
values from the Tukey’s post-hoc tests. Running a corrected script shows lower p-values for the 
comparisons of lovastatin and simvastatin in Fmr1-/y mice than originally published (Table 3). 
Additionally, Ottenhoff et al. run a Type 1 ANOVA that assumes an interaction between genotype 
and treatment, which we do not claim (nor can we with such a low incidence of seizures in WT). 
Re-running the logistical regression using a Type 2 ANOVA that does not assume an interaction 
shows a trend towards a main effect of treatment, though this does not reach significance (p = 
0.053). However our original study was not powered to directly compare treatment groups, and we 
therefore investigated whether adding an additional treatment group would change the outcome of 
this analysis. In the original study testing lovastatin in Fmr1-/y mice, multiple drug doses were tested 
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in both FVB and C57BL6 background strains (Osterweil et al., 2013) (Fig. 1C). After adding the 
data from the FVB group treated with 100 mg/kg lovastatin in this study, we re-ran the logistical 
regression and find a significant effect of treatment (p = 0.00021). When both lovastatin groups are 
collapsed, the significance of this effect increases (p = 9.22 X 10 -5).  Adding all lovastatin groups 
from Osterweil et al. 2013 increases the significance further (p = 8.08 X 10-9) (Table 4). Therefore, 
the logistical regression identifies the difference in treatment when given a dataset of sufficient size. 
Moreover, we find that a multinominal regression model that examines seizure severity scores 
reveals a significant treatment effect, even when applied to the original dataset from Muscas et al. 
2019 (p = 0.033) (Table 4; Extended data). The important conclusion is that whether our results 
are analyzed directly or fit to a more complex model, they show that lovastatin corrects the AGS 
phenotype in Fmr1-/y mice, and simvastatin does not. 
 
Future considerations 
Our studies in Fmr1-/y animal models show promising results for lovastatin that are not seen 
with simvastatin. However, it is important to note that the role of statins in the treatment of Fragile 
X and other neurodevelopmental disorders will ultimately depend on large scale double-blind 
placebo-controlled trials. In the case of lovastatin, the results from double-blind placebo-controlled 
trials for NF1 are mixed, with one showing a significant improvement in verbal and nonverbal 
memory (Bearden et al., 2016), and another showing no significant effect on visuospatial learning 
and attention (Payne et al., 2016). In FX, a recent small-scale double-blind trial showed no 
additional effect of lovastatin on parent implemented language intervention (Thurman et al., 2020). 
For simvastatin, three randomized placebo controlled clinical trials have failed to show efficacy in 
NF1 (Table 2). At present, our study represents the only exploration of simvastatin in an animal 
model of neurodevelopmental disorders. We agree with Ottenhoff et al. that “importance of looking 
at effective dosing ranges, and more detailed (in vivo) pharmacological studies in animal models 
should be performed to elucidate the dose-dependency of therapeutic benefit.” Whether simvastatin 
shows benefits in FX or other models using a specific dosing regimen or alternative behavioral 
assays is an open question that would be very informative for future clinical studies. What is clear 
from our initial work is that there are significant differences between the action of lovastatin and 
simvastatin on brain function that warrant further attention. 
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Figure and table legends: 
Table 1. Animal model studies of lovastatin and simvastatin in neurodevelopmental disorders. 
Studies using animal models of neurodevelopmental disorders have tested the impact of lovastatin 
on multiple phenotypes. Ours is the only study of simvastatin in a neurodevelopmental animal 
model.  
Abbreviations: i.p.: intraperitoneal, s.c.: subcutaneous, mGluR-LTD: metabotropic glutamate 
receptor stimulated long-term depression, LTP: long-term potentiation, PFC: prefrontal cortex, 
ERK: extracellular-regulated kinase, MWM: Morris Water Maze, PPI: pre-pulse inhibition 
 
Table 2. Human studies of lovastatin and simvastatin in neurodevelopmental disorders. 
Lovastatin and simvastatin have been tested in clinical trials for FX and NF1, with varying 
outcomes. 
Abbreviations: RCT: randomized placebo-controlled trial; ABC: aberrant behaviour checklist, CGI-
S: clinical global impression scale, MRI: magnetic resonance imaging, ERK: extracellular-regulated 
kinase, GABA: gamma-Aminobutyric acid 
 
Table 3. Reordered comparisons reveal correct p values for Tukey’s post-hoc tests.   The 
regression model R script used by Ottenhoff et al. assigns different functions to set up the 
regression model matrix (“Unique”) versus the Tukey’s contrast matrix (“Tables”). This results in 
different order of groups for the two matrices which results in assignment of different headings to 
the test results. An altered version of the script with the factors level set in the same order for the 
model matrix and contrast matrix shows the correct Tukey’s test results (see Extended Data). 
Estimate and z value are multiplied by -1 to reflect the corresponding tests headings. Reversed 
values are italicized and the corrected p-values reported by Ottenhoff are in bold. 
 
Table 4. Regression model of AGS incidence and severity shows significant treatment effect in 
lovastatin versus simvastatin groups.  Re-running the logistical regression comparing lovastatin 
and simvastatin treatments using a Type 2 ANVOA shows a non-significant trend towards an effect 
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of treatment. Adding data from the FVB 100 mg/kg lovastatin group originally published in 
Osterweil et al. 2013 shows a significant treatment effect either when kept separate or when 
collapsed into the existing lovastatin group. Adding data from additional lovastatin treatment 
groups from C57BL6 cohorts from Osterweil et al. 2013 (10 mg/kg, 30 mg/kg and 100 mg/kg) 
further increases the significance of the treatment effect. As the interaction of genotype and 
treatment does not reach significance using this model, it may be that lovastatin corrects seizures in 
both WT and Fmr1-/y mice equally, however the low number of animals have seizures in the WT 
groups makes this difficult to assess. To compare lovastatin versus simvastatin treatment groups, a 
multinomial regression model of seizure severity scores with genotype and treatment effect was 
performed in R using the multinom function in the nnet package (see Extended Data). 
 
Figure 1. Lovastatin, not simvastatin, corrects fragile X phenotypes. (A) Data from (Osterweil 
et al., 2013) and (Muscas et al., 2019) were combined and re-analysed. Metabolic labelling was 
performed on hippocampal slices prepared from WT/Fmr1-/y littermates as previously described. A 
dose-response curve shows lovastatin corrects excess protein synthesis in the Fmr1-/y hippocampus 
at 50 µM (Two-way repeated measures mixed-model ANOVA treatment p = 0.0052, genotype p = 
0.0006, genotype x treatment p =  0.0438; Sidak’s WT veh vs KO veh *p = 0.0021, KO veh vs KO 
50 *p = 0.0014). In contrast, simvastatin significantly raises protein synthesis in a dose-dependent 
manner in both Fmr1-/y and WT hippocampus (Two-way repeated measures mixed-model ANOVA 
treatment p < 0.0001, genotype p = 0.0005, genotype x treatment p =  0.9754, Sidak’s WT veh vs 
WT 0.5 *p = 0.0120, WT veh vs WT 5 *p < 0.0001, KO veh vs KO 0.5 *p = 0.0157, KO veh vs KO 
5 *p < 0.0001 ). (B) Data re-plotted from (Muscas et al., 2019) (Figure 1-1). AGS assays show that 
acute injection of 100 mg/kg lovastatin significantly reduces the incidence of seizures in Fmr1-/y 
mice versus vehicle control (Fisher’s Exact test *p = 0.0136). Conversely, neither an equipotent 
dose of 50 mg/kg simvastatin (Fisher’s Exact test p = 0.6968) nor a lower 3 mg/kg dose 
significantly (Fisher’s Exact test p > 0.999) impacts the incidence of seizures in the Fmr1-/y mouse. 
(C) AGS results from (Muscas et al., 2019) and (Osterweil et al., 2013) show that although 
simvastatin fails to reduce seizures, lovastatin significantly reduces seizures when given at 10 
mg/kg orally (p.o.) for 2 days, 30 mg/kg injection i.p., or 100 mg/kg injection i.p. in Fmr1-/y mice 
on both C57BL6 and FVB background strains (Fisher’s Exact test: 10 mg/kg *p = 0.003, 30 mg/kg 
*p = 0.041, 100 mg/kg C57 *p = 0.005, 100 mg/kg FVB *p = 0.005) (Figure 1-2, Figure 1-3). 
 
Extended Data: 




Figure 1-1. Original dataset from Muscas et al. 2019 
 
 




Figure 1-3. Combined dataset from Muscas et al. 2019 and 4 datasets from Osterweil et al. 2013 
 
 
 
 
 
